Breakthrough Oral Drug Shows Promise Against Deadly Fungal Infections

London, Thursday, 18 June 2026.
A new oral antifungal, olorofim, achieved a 23.8% mortality rate in a Phase 3 trial—matching the standard treatment but with fewer side effects. If approved, it could be the first novel antifungal in over 20 years, offering hope for patients with life-threatening infections.